Phase II Biomarker Trial of a Multimarker Diagnostic for Ovarian Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2010 Jan 19

PMID 20082099

Citations 40

Authors

Tracey Edgell

G Martin-Roussety

G Barker

D J Autelitano

D Allen

P Grant

G E Rice

Affiliations

Soon will be listed here.

Abstract

Purpose: The primary hypothesis to be tested in this study was that the diagnostic performance (as assessed by the area under the receiver operator characteristic curve, AUC) of a multianalyte panel to correctly identify women with ovarian cancer was significantly greater than that for CA-125 alone.

Methods: A retrospective, case-control study (phase II biomarker trial) was conducted that involved 362 plasma samples obtained from women with ovarian cancer (n = 150) and healthy controls (n = 212). A multivariate classification model was developed that incorporated five biomarkers of ovarian cancer, CA-125; C-reactive protein (CRP); serum amyloid A (SAA); interleukin 6 (IL-6); and interleukin 8 (IL-8) from a modelling cohort (n = 179). The performance of the model was evaluated using an independent validation cohort (n = 183) and compared with of CA-125 alone.

Results: The AUC for the biomarker panel was significantly greater than the AUC for CA-125 alone for a validation cohort (p < 0.01) and an early stage disease cohort (i.e. Stages I and II; p < 0.01). At a threshold of 0.3, the sensitivity and specificity of the multianalyte panel were 94.1 and 91.3%, respectively, for the validation cohort and 92.3 and 91.3%, respectively for an early stage disease cohort.

Conclusions: The use of a panel of plasma biomarkers for the identification of women with ovarian cancer delivers a significant increase in diagnostic performance when compared to the performance of CA-125 alone.

Citing Articles

Unlocking ovarian cancer heterogeneity: advancing immunotherapy through single-cell transcriptomics.

Balan D, Kampan N, Plebanski M, Abd Aziz N Front Oncol. 2024; 14:1388663.

PMID: 38873253 PMC: 11169633. DOI: 10.3389/fonc.2024.1388663.

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer.

Song J, Sokoll L, Zhang Z, Chan D Clin Proteomics. 2023; 20(1):25.

PMID: 37357306 PMC: 10291808. DOI: 10.1186/s12014-023-09414-z.

Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses.

Kampan N, Kartikasari A, Deceneux C, Madondo M, McNally O, Flanagan K Cancers (Basel). 2023; 15(3).

PMID: 36765633 PMC: 9913655. DOI: 10.3390/cancers15030667.

Differential expression of Chitinase 3-Like 1 protein in appendicitis and appendix carcinomas.

Zhang Y, Li Y, Li F, Li L, Wang C, Wang H J Clin Lab Anal. 2022; 36(12):e24790.

PMID: 36447423 PMC: 9756995. DOI: 10.1002/jcla.24790.

Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.

Liberto J, Chen S, Shih I, Wang T, Wang T, Pisanic 2nd T Cancers (Basel). 2022; 14(12).

PMID: 35740550 PMC: 9221480. DOI: 10.3390/cancers14122885.

References

Moshkovskii S, Serebryakova M, Kuteykin-Teplyakov K, Tikhonova O, Goufman E, Zgoda V . Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics. 2005; 5(14):3790-7. DOI: 10.1002/pmic.200401205. View

Paley P . Ovarian cancer screening: are we making any progress?. Curr Opin Oncol. 2001; 13(5):399-402. DOI: 10.1097/00001622-200109000-00015. View

May A, Wang T . Biomarkers for cardiovascular disease: challenges and future directions. Trends Mol Med. 2008; 14(6):261-7. DOI: 10.1016/j.molmed.2008.04.003. View

Weinstein P, Skinner M, Sipe J, Lokich J, ZAMCHECK N, Cohen A . Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol. 1984; 19(3):193-8. DOI: 10.1111/j.1365-3083.1984.tb00919.x. View

Bast Jr R, Klug T, St John E, Jenison E, Niloff J, Lazarus H . A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309(15):883-7. DOI: 10.1056/NEJM198310133091503. View

Nustad K, Bast Jr R, Brien T, Nilsson O, Seguin P, Suresh M . Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol. 1996; 17(4):196-219. DOI: 10.1159/000217982. View

Avall Lundqvist E, Nordstrom L, Sjovall K, Eneroth P . Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies. Eur J Gynaecol Oncol. 1989; 10(6):395-405. View

Zurawski Jr V, Orjaseter H, Andersen A, Jellum E . Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988; 42(5):677-80. DOI: 10.1002/ijc.2910420507. View

Bertenshaw G, Yip P, Seshaiah P, Zhao J, Chen T, Wiggins W . Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(10):2872-81. DOI: 10.1158/1055-9965.EPI-08-0464. View

10.

Gorelik E, Landsittel D, Marrangoni A, Modugno F, Velikokhatnaya L, Winans M . Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14(4):981-7. DOI: 10.1158/1055-9965.EPI-04-0404. View

11.

Jacobs I, Davies A, Bridges J, Stabile I, Fay T, Lower A . Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993; 306(6884):1030-4. PMC: 1677033. DOI: 10.1136/bmj.306.6884.1030. View

12.

Helleman J, Van der Vlies D, Jansen M, Luider T, van der Burg M, Stoter G . Serum proteomic patterns for ovarian cancer monitoring. Int J Gynecol Cancer. 2007; 18(5):985-95. DOI: 10.1111/j.1525-1438.2007.01139.x. View

13.

Maccio A, Lai P, Santona M, Pagliara L, Melis G, Mantovani G . High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998; 69(3):248-52. DOI: 10.1006/gyno.1998.4974. View

14.

Coates R, Kolor K, Stewart S, Richardson L . Diagnostic markers for ovarian cancer screening: not ready for routine clinical use. Clin Cancer Res. 2008; 14(22):7575-6. DOI: 10.1158/1078-0432.CCR-08-2296. View

15.

Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y . Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999; 82(1):107-10. DOI: 10.1016/s0301-2115(98)00227-9. View

16.

Geisler J, Miller G, Lee T, Harwood R, Wiemann M, Geisler H . Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. J Reprod Med. 1996; 41(3):140-2. View

17.

Andersen M, Goff B, Lowe K, Scholler N, Bergan L, Dresher C . Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer. 2008; 113(3):484-9. PMC: 2734274. DOI: 10.1002/cncr.23577. View

18.

McSorley M, Alberg A, Allen D, Allen N, Brinton L, Dorgan J . C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007; 109(4):933-41. DOI: 10.1097/01.AOG.0000257126.68803.03. View

19.

Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W . Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol Immunol. 2005; 2(5):365-72. View

20.

Pepys M, Baltz M . Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983; 34:141-212. DOI: 10.1016/s0065-2776(08)60379-x. View